Theranostics-a rapidly advancing field that integrates diagnostic imaging with targeted radiotherapy-holds great promise for revolutionizing cancer care. As this paradigm expands, a major challenge to its success lies in building and sustaining a skilled workforce, particularly in radiopharmaceutical development and delivery. A critical yet underrecognized member of this workforce is the nuclear pharmacist (also referred to as a radiopharmacist). Traditionally tasked with the preparation and dispensing of radiopharmaceuticals, nuclear pharmacists are increasingly stepping into clinical roles, especially in academic and theranostic-focused centers. These professionals bring expertise in radiochemistry, pharmacology, regulatory compliance, and patient care-making them uniquely suited to support the growing complexity of theranostic therapies. This article highlights the evolution of radiopharmacy, the specialized training of clinical nuclear pharmacists, and their expanding role in patient-centered care. Emphasizing collaborative practice models and future educational pathways, we argue that integrating clinical nuclear pharmacists into theranostic teams will enhance safety, efficiency, and therapeutic outcomes in this transformative area of medicine.
Kara Weatherman (Mon,) studied this question.